Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.